- Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
-
A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.
- Okawa, Tomohiro,Aramaki, Yoshio,Yamamoto, Mitsuo,Kobayashi, Toshitake,Fukumoto, Shoji,Toyoda, Yukio,Henta, Tsutomu,Hata, Akito,Ikeda, Shota,Kaneko, Manami,Hoffman, Isaac D.,Sang, Bi-Ching,Zou, Hua,Kawamoto, Tetsuji
-
p. 6942 - 6990
(2017/09/07)
-
- CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
There is provided compounds of formula I, (I) wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
- -
-
Page/Page column 108
(2017/03/14)
-
- AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES
-
The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
- -
-
Page/Page column 128
(2013/09/12)
-
- PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES
-
Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.
- -
-
Page/Page column 79; 80
(2013/09/12)
-
- AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES
-
Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
- -
-
Page/Page column 141
(2013/09/12)
-
- AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES
-
Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.
- -
-
Page/Page column 57; 58
(2013/09/12)
-
- AMIDO-BENZYL SULFOXIDE DERIVATIVES
-
The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat
- -
-
Paragraph 0166
(2013/09/12)
-
- ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES
-
The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,
- -
-
Paragraph 0174
(2013/09/12)
-
- AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE
-
The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
- -
-
Page/Page column 68
(2008/06/13)
-
- Raf inhibitor compounds and methods of use thereof
-
Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
- -
-
Page/Page column 78; 30-31
(2010/11/26)
-
- FUSED FURAN COMPOUND
-
The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R3 is hydrogen or the like; and , R4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.
- -
-
Page/Page column 131-132
(2008/06/13)
-
- NOVEL COMPOUNDS
-
The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their prepa
- -
-
Page/Page column 36
(2010/02/12)
-
- Furopyridines. V. A Simple Synthesis of Furopyridine and Its 2- and 3-Methyl Derivatives
-
A simple synthesis of furopyridine and its 2- and 3-methyl derivatives from ethyl 3-hydroxyisonicotinate (2) is described.The hydroxy ester 2 was O-alkylated with ethyl bromoacetate or ethyl 2-bromopropionate to give the diester 3a or 3b.Cyclization of compound 3a afforded ethyl 3-hydroxyfuropyridine-2-carboxylate (4) which was hydrolyzed and decarboxylated to give furopyridin-3(2H)-one (5a).Cyclization of 3b gave the 2-methyl derivative 5b.Reduction of 5a and 5b with sodium borohydride yielded the corresponding hydroxy derivative 6a and 6b, respectively, which were dehydrated with phosphoric acid to give furopyridine (7a) and its 2-methyl derivative 7b. 4-Acetylpyridin-3-ol (8) was O-alkylated with ethyl bromoacetate to give ethyl 2-(4-acetyl-3-pyridyloxy)acetate (9).Saponification of compound 9, and the subsequent intramolecular Perkin reaction gave 3-methylfuropyridine (10).Cyclization of 9 with sodium ethoxide gave 3-methylfuropyridine-2-carboxylic acid, which in turn was decarboxylated to give compound 10.
- Morita, Hiroyuki,Shiotani, Shunsaku
-
p. 549 - 552
(2007/10/02)
-